-
Adaptive designs for Phase II oncology trials
Meinhard Kieser, Stefan Englert, Geraldine Rauch
Commentary: Clinical Investigation
-
Adaptive designs for Phase II oncology trials
Meinhard Kieser, Stefan Englert, Geraldine Rauch
Commentary: Clinical Investigation
-
Adaptive designs for Phase II oncology trials
Meinhard Kieser, Stefan Englert, Geraldine Rauch
Commentary: Clinical Investigation
-
Adaptive designs for Phase II oncology trials
Meinhard Kieser, Stefan Englert, Geraldine Rauch
Commentary: Clinical Investigation
-
Adaptive designs for Phase II oncology trials
Meinhard Kieser, Stefan Englert, Geraldine Rauch
Commentary: Clinical Investigation
-
Adaptive designs for Phase II oncology trials
Meinhard Kieser, Stefan Englert, Geraldine Rauch
Commentary: Clinical Investigation
-
Adaptive designs for Phase II oncology trials
Meinhard Kieser, Stefan Englert, Geraldine Rauch
Commentary: Clinical Investigation
-
Adaptive designs for Phase II oncology trials
Meinhard Kieser, Stefan Englert, Geraldine Rauch
Commentary: Clinical Investigation
-
How can we effectively identify and report clinical research misconduct?
Glenda Guest
Editorial: Clinical Investigation
-
How can we effectively identify and report clinical research misconduct?
Glenda Guest
Editorial: Clinical Investigation
-
How can we effectively identify and report clinical research misconduct?
Glenda Guest
Editorial: Clinical Investigation
-
How can we effectively identify and report clinical research misconduct?
Glenda Guest
Editorial: Clinical Investigation
-
How can we effectively identify and report clinical research misconduct?
Glenda Guest
Editorial: Clinical Investigation
-
How can we effectively identify and report clinical research misconduct?
Glenda Guest
Editorial: Clinical Investigation
-
How can we effectively identify and report clinical research misconduct?
Glenda Guest
Editorial: Clinical Investigation
-
How can we effectively identify and report clinical research misconduct?
Glenda Guest
Editorial: Clinical Investigation
-
Neuroprotective agents in ischemic stroke: past failures and future opportunities
Jiangyong Min, Muhammad U Farooq, Philip B Gorelick
Review: Clinical Trail Outcomes: Clinical Investigation
-
Neuroprotective agents in ischemic stroke: past failures and future opportunities
Jiangyong Min, Muhammad U Farooq, Philip B Gorelick
Review: Clinical Trail Outcomes: Clinical Investigation
-
Neuroprotective agents in ischemic stroke: past failures and future opportunities
Jiangyong Min, Muhammad U Farooq, Philip B Gorelick
Review: Clinical Trail Outcomes: Clinical Investigation
-
Neuroprotective agents in ischemic stroke: past failures and future opportunities
Jiangyong Min, Muhammad U Farooq, Philip B Gorelick
Review: Clinical Trail Outcomes: Clinical Investigation
-
Neuroprotective agents in ischemic stroke: past failures and future opportunities
Jiangyong Min, Muhammad U Farooq, Philip B Gorelick
Review: Clinical Trail Outcomes: Clinical Investigation
-
Neuroprotective agents in ischemic stroke: past failures and future opportunities
Jiangyong Min, Muhammad U Farooq, Philip B Gorelick
Review: Clinical Trail Outcomes: Clinical Investigation
-
Neuroprotective agents in ischemic stroke: past failures and future opportunities
Jiangyong Min, Muhammad U Farooq, Philip B Gorelick
Review: Clinical Trail Outcomes: Clinical Investigation
-
Neuroprotective agents in ischemic stroke: past failures and future opportunities
Jiangyong Min, Muhammad U Farooq, Philip B Gorelick
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical trials in pediatric multiple sclerosis: overcoming the challenges
Sunita Venkateswaran, Brenda Banwell
Clinical Trail Methodology: Clinical Investigation
-
Clinical trials in pediatric multiple sclerosis: overcoming the challenges
Sunita Venkateswaran, Brenda Banwell
Clinical Trail Methodology: Clinical Investigation
-
Clinical trials in pediatric multiple sclerosis: overcoming the challenges
Sunita Venkateswaran, Brenda Banwell
Clinical Trail Methodology: Clinical Investigation
-
Clinical trials in pediatric multiple sclerosis: overcoming the challenges
Sunita Venkateswaran, Brenda Banwell
Clinical Trail Methodology: Clinical Investigation
-
Clinical trials in pediatric multiple sclerosis: overcoming the challenges
Sunita Venkateswaran, Brenda Banwell
Clinical Trail Methodology: Clinical Investigation
-
Clinical trials in pediatric multiple sclerosis: overcoming the challenges
Sunita Venkateswaran, Brenda Banwell
Clinical Trail Methodology: Clinical Investigation
-
Clinical trials in pediatric multiple sclerosis: overcoming the challenges
Sunita Venkateswaran, Brenda Banwell
Clinical Trail Methodology: Clinical Investigation
-
Clinical trials in pediatric multiple sclerosis: overcoming the challenges
Sunita Venkateswaran, Brenda Banwell
Clinical Trail Methodology: Clinical Investigation
-
Results and implications of the Trastuzumab for Gastric Cancer (ToGA) trial
Dok Hyun Yoon1 & Yoon-Koo Kang
Review Article: Clinical Investigation
-
Results and implications of the Trastuzumab for Gastric Cancer (ToGA) trial
Dok Hyun Yoon1 & Yoon-Koo Kang
Review Article: Clinical Investigation
-
Results and implications of the Trastuzumab for Gastric Cancer (ToGA) trial
Dok Hyun Yoon1 & Yoon-Koo Kang
Review Article: Clinical Investigation
-
Results and implications of the Trastuzumab for Gastric Cancer (ToGA) trial
Dok Hyun Yoon1 & Yoon-Koo Kang
Review Article: Clinical Investigation
-
Results and implications of the Trastuzumab for Gastric Cancer (ToGA) trial
Dok Hyun Yoon1 & Yoon-Koo Kang
Review Article: Clinical Investigation
-
Results and implications of the Trastuzumab for Gastric Cancer (ToGA) trial
Dok Hyun Yoon1 & Yoon-Koo Kang
Review Article: Clinical Investigation
-
Results and implications of the Trastuzumab for Gastric Cancer (ToGA) trial
Dok Hyun Yoon1 & Yoon-Koo Kang
Review Article: Clinical Investigation
-
Results and implications of the Trastuzumab for Gastric Cancer (ToGA) trial
Dok Hyun Yoon1 & Yoon-Koo Kang
Review Article: Clinical Investigation